FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 302:1047-1051 May 8, 1980 Number 19 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

The form of von Willebrand's disease characterized by a qualitative abnormality of Factor VIII/von Willebrand factor (FVIII/vWF) in plasma has been designated as Type II. We have now identified 20 persons from five families whose qualitatively abnormal FVIII/vWF shows heightened responsiveness to ristocetin. We have classified this form of the disease as Type IIB and reclassified as Type IIA the form previously described as Type II, in which the interaction of the abnormal FVIII/vWF with platelets is decreased or absent in the presence of ristocetin. The enhanced reactivity of FVIII/vWF in Type IIB was evident in studies of ristocetin-induced platelet agglutination and of binding of FVIII/vWF to platelets in the presence of ristocetin. In both Type IIA and IIB, crossed immunoelectrophoresis of plasma FVIII/vWF demonstrated similar absence of the larger, less anodic forms. These findings suggest that ristocetin-mediated interactions between platelets and FVIII/vWF do not accurately reflect the "bleeding-time" (von Willebrand factor) defect in this newly described subtype of von Willebrand's disease.

This article has been cited by other articles:

• Dunois-Larde, C., Capron, C., Fichelson, S., Bauer, T., Cramer-Borde, E., Baruch, D. (2009). Exposure of human megakaryocytes to high shear rates accelerates platelet production. Blood 114: 1875-1883 [Abstract] [Full Text]  
• Federici, A. B, Canciani, M. T. (2009). Clinical and laboratory versus molecular markers for a correct classification of von Willebrand disease. haematol 94: 610-615 [Full Text]  
• Jackson, S. C., Sinclair, G. D., Cloutier, S., Duan, Z., Rand, M. L., Poon, M.-C. (2009). The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutation. Blood 113: 3348-3351 [Abstract] [Full Text]  
• Montgomery, R. R. (2009). At least Type VWD2B is a discrete variant of VWD, isn't it?. Blood 113: 501-501 [Full Text]  
• Federici, A. B., Mannucci, P. M., Castaman, G., Baronciani, L., Bucciarelli, P., Canciani, M. T., Pecci, A., Lenting, P. J., De Groot, P. G. (2009). Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood 113: 526-534 [Abstract] [Full Text]  
• Giannini, S., Mezzasoma, A. M., Leone, M., Gresele, P. (2007). Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry. haematol 92: 1647-1654 [Abstract] [Full Text]  
• Ruggeri, Z. M., Mendolicchio, G. L. (2007). Adhesion Mechanisms in Platelet Function. Circ. Res. 100: 1673-1685 [Abstract] [Full Text]  
• Quiroga, T., Goycoolea, M., Panes, O., Aranda, E., Martinez, C., Belmont, S., Munoz, B., Zuniga, P., Pereira, J., Mezzano, D. (2007). High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls. haematol 92: 357-365 [Abstract] [Full Text]  
• Federici, A. B. (2006). Impaired megakaryocytopoiesis in type 2B von Willebrand disease. Blood 108: 2498-2499 [Full Text]  
• Nurden, P., Debili, N., Vainchenker, W., Bobe, R., Bredoux, R., Corvazier, E., Combrie, R., Fressinaud, E., Meyer, D., Nurden, A. T., Enouf, J. (2006). Impaired megakaryocytopoiesis in type 2B von Willebrand disease with severe thrombocytopenia. Blood 108: 2587-2595 [Abstract] [Full Text]  
• De Cristofaro, R., Peyvandi, F., Baronciani, L., Palla, R., Lavoretano, S., Lombardi, R., Di Stasio, E., Federici, A. B., Mannucci, P. M. (2006). Molecular Mapping of the Chloride-binding Site in von Willebrand Factor (VWF): ENERGETICS AND CONFORMATIONAL EFFECTS ON THE VWF/ADAMTS-13 INTERACTION. J. Biol. Chem. 281: 30400-30411 [Abstract] [Full Text]  
• Michiels, J. J., Berneman, Z., Gadisseur, A., van der Planken, M., Schroyens, W., van de Velde, A., van Vliet, H. (2006). Classification and Characterization of Hereditary Types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (Unclassifiable) von Willebrand Disease. CLIN APPL THROMB HEMOST 12: 397-420 [Abstract]  
• Hulstein, J. J. J., de Groot, P. G., Silence, K., Veyradier, A., Fijnheer, R., Lenting, P. J. (2005). A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood 106: 3035-3042 [Abstract] [Full Text]  
• Nishio, K., Anderson, P. J., Zheng, X. L., Sadler, J. E. (2004). Binding of platelet glycoprotein Ib{alpha} to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proc. Natl. Acad. Sci. USA 101: 10578-10583 [Abstract] [Full Text]  
• Dumas, J. J., Kumar, R., McDonagh, T., Sullivan, F., Stahl, M. L., Somers, W. S., Mosyak, L. (2004). Crystal Structure of the Wild-type von Willebrand Factor A1-Glycoprotein Ib{alpha} Complex Reveals Conformation Differences with a Complex Bearing von Willebrand Disease Mutations. J. Biol. Chem. 279: 23327-23334 [Abstract] [Full Text]  
• Caramuru, L. H., Soares, R. D. P. S., Maeda, N. Y., Lopes, A. A. (2003). Hypoxia and Altered Platelet Behavior Influence von Willebrand Factor Multimeric Composition in Secondary Pulmonary Hypertension. CLIN APPL THROMB HEMOST 9: 251-258 [Abstract]  
• Doggett, T. A., Girdhar, G., Lawshe, A., Miller, J. L., Laurenzi, I. J., Diamond, S. L., Diacovo, T. G. (2003). Alterations in the intrinsic properties of the GPIb{alpha}-VWF tether bond define the kinetics of the platelet-type von Willebrand disease mutation, Gly233Val. Blood 102: 152-160 [Abstract] [Full Text]  
• Casonato, A., Pontara, E., Sartorello, F., Cattini, M. G., Sartori, M. T., Padrini, R., Girolami, A. (2002). Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood 99: 180-184 [Abstract] [Full Text]  
• Pareti, F. I., Lattuada, A., Bressi, C., Zanobini, M., Sala, A., Steffan, A., Ruggeri, Z. M. (2000). Proteolysis of von Willebrand Factor and Shear Stress-Induced Platelet Aggregation in Patients With Aortic Valve Stenosis. Circulation 102: 1290-1295 [Abstract] [Full Text]  
• Marchese, P., Saldivar, E., Ware, J., Ruggeri, Z. M. (1999). Adhesive properties of the isolated amino-terminal domain of platelet glycoprotein Ibalpha in a flow field. Proc. Natl. Acad. Sci. USA 96: 7837-7842 [Abstract] [Full Text]  
• Allen, G. C., Armfield, D. R., Bontempo, F. A., Kingsley, L. A., Goldstein, N. A., Post, J. C. (1999). Adenotonsillectomy in Children With von Willebrand Disease. Arch Otolaryngol Head Neck Surg 125: 547-551 [Abstract] [Full Text]  
• Mauz-Körholz, C, Budde, U, Kruck, H, Körholz, D, Göbel, U (1998). Management of severe chronic thrombocytopenia in von Willebrand's disease type 2B. Arch. Dis. Child. 78: 257-260 [Abstract] [Full Text]  
• Schulte am Esch II, J., Cruz, M. A., Siegel, J. B., Anrather, J., Robson, S. C. (1997). Activation of Human Platelets by the Membrane-Expressed A1 Domain of von Willebrand Factor. Blood 90: 4425-4437 [Abstract] [Full Text]  
• Miyata, S., Goto, S., Federici, A. B., Ware, J., Ruggeri, Z. M. (1996). Conformational Changes in the A1 Domain of von Willebrand Factor Modulating the Interaction with Platelet Glycoprotein Ibalpha. J. Biol. Chem. 271: 9046-9053 [Abstract] [Full Text]  
• KRIZEK, D. M., RICK, M. E., WILLIAMS, S. B., GRALNICK, H. R. (1983). Cryoprecipitate Transfusion in Variant von Willebrand's Disease and Thrombocytopenia. ANN INTERN MED 98: 484-486 [Abstract]  
• WEINGER, R. S., CIMO, P. L., MOAKE, J. L., OLSON, J. D., HELLER, M. S. (1981). Type IIB von Willebrand's Disease: Unusual Response to Cryoprecipitate Infusion. ANN INTERN MED 94: 47-50 [Abstract]